MetabPlus
A flexible and efficient multi-IEM, Newborn Screening Program
Introduction to MetabPlus
The main objective of the project is the clinical validation of an array for the early detection of IEMs (innate Errors of Metabolism) in a large number of dried blood samples (DBS) from neonates. The initial panel will be chosen from a large library of proprietary enzyme substrates associated with specific IEMs. The MetabPlus array will be designed and transferred to clinical practice as a competitive highly multiplexed newborn screening tool.
IEMs represent the largest group of rare diseases with 2,000 types identified that are believed to affect more than 1 in 200 live births. Currently, only thirty or so of these diseases can be detected in neonatal screening programs.
However, there is a very strong clinical need to be able to progressively expand the number of IEMs that are screened in neonates since many of these diseases have an effective treatment and could be prevented or the morbidity and mortality associated with them could be reduced for other IEMs that are not commonly screened for in these programs today.
The most important barrier to making a disruptive leap in the early detection of IEMs is the lack of availability of a highly multiplexed technique that can facilitate the detection of hundreds of these IEMs and can be marketed at a reasonable price so that this new screening is cost-effective. MetabPlus aims to validate such a solution.
THE CONSORTIUM
La Fundación Pública Andaluza para la Investigación de Málaga en Biomedicina y (FIMABIS)
The Public Foundation for Health and Biomedicine Research in Málaga (FIMABIS, for its initials in Spanish) is an organisation dedicated to seamlessly integrating basic, clinical and public health research by promoting, conducting and disseminating scientific research in the biomedicine, clinical care and biotechnology areas. It provides effective support for innovation in the life sciences and serves as a link between health and research centres and their social and geographical setting.
FIMABIS is currently the managing entity of the Biomedical Research Institute of Málaga and Nanomedicine Platform (IBIMA Plataforma BIONAND, for its initials in Spanish) and represents it.
IBIMA Plataforma BIONAND is a Health Research Institute created on 19 March 2012 by virtue of the agreement signed between the Regional Ministry of Health; the Regional Ministry of Economy, Innovation and Science; the Andalusian Health Service; the University of Málaga; and the Andalusian Public Foundation for Health and Biomedicine Research in Málaga. In addition, it is one of the more than 30 institutes accredited for health research in Spain by the Carlos III Institute of Health.
Reactomix
Reactomix is a biotech start-up based in Granada, Spain.
We are focused on advancing the use of enzymolomics enzymes in research, in industry, as well as in the clinic.
Our aim is to use our unique enzymolomic platform technology to revolutionise newborn screening testing for metabolic disorders. We are also developing a much higher plex tool for R&D applications to advance our understanding of diseases and to help in the development of novel therapeutic applications.
Our technology is licensed from the Spanish National Research Council (CSIC) in Madrid, Spain and the Helmholtz Center for infection Research (HZI) in Braunschweig, Germany.
Pioneering Neonatal Screening Solutions
At MetabPlus.com, based in Málaga, España, we are dedicated to advancing the field of neonatal screening. Our mission is to ensure early and accurate detection of metabolic disorders in newborns, providing peace of mind for families and healthcare professionals alike. By harnessing cutting-edge technology and scientific expertise, we strive to deliver reliable solutions that transform infant care and health outcomes.
Contact us
MetabPlus Funding
MetabPlus has been made possible by the Spanish Ministry of Science and Innovation with money from the NextGenerationEU funds.
